MX2021004496A - Activadores segmentables de cxcr3 y metodos de uso. - Google Patents

Activadores segmentables de cxcr3 y metodos de uso.

Info

Publication number
MX2021004496A
MX2021004496A MX2021004496A MX2021004496A MX2021004496A MX 2021004496 A MX2021004496 A MX 2021004496A MX 2021004496 A MX2021004496 A MX 2021004496A MX 2021004496 A MX2021004496 A MX 2021004496A MX 2021004496 A MX2021004496 A MX 2021004496A
Authority
MX
Mexico
Prior art keywords
cxcl
cxcr3
protease
cleavable
activators
Prior art date
Application number
MX2021004496A
Other languages
English (en)
Spanish (es)
Inventor
Alan H Wells
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of MX2021004496A publication Critical patent/MX2021004496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2021004496A 2018-10-22 2019-10-18 Activadores segmentables de cxcr3 y metodos de uso. MX2021004496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Publications (1)

Publication Number Publication Date
MX2021004496A true MX2021004496A (es) 2021-06-04

Family

ID=70330587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004496A MX2021004496A (es) 2018-10-22 2019-10-18 Activadores segmentables de cxcr3 y metodos de uso.

Country Status (12)

Country Link
US (2) US12110316B2 (enExample)
EP (1) EP3870212A4 (enExample)
JP (3) JP7426121B2 (enExample)
KR (1) KR20210081372A (enExample)
CN (2) CN120022352A (enExample)
AU (2) AU2019365654B2 (enExample)
BR (1) BR112021007414A2 (enExample)
CA (1) CA3116325A1 (enExample)
IL (2) IL324815A (enExample)
MX (1) MX2021004496A (enExample)
SG (1) SG11202103497WA (enExample)
WO (1) WO2020086400A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081372A (ko) * 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
WO2024118744A2 (en) * 2022-11-30 2024-06-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr3-activating peptides for controlled release in ophthalmic and topical treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
US9180167B2 (en) 2011-08-26 2015-11-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Activators of CXCR3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
AU2014306074B2 (en) * 2013-08-05 2018-08-30 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US9895419B2 (en) * 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
ES2738582T3 (es) * 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20210081372A (ko) 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법

Also Published As

Publication number Publication date
EP3870212A1 (en) 2021-09-01
SG11202103497WA (en) 2021-05-28
JP2022512770A (ja) 2022-02-07
US20250002549A1 (en) 2025-01-02
BR112021007414A2 (pt) 2021-08-10
US20210388048A1 (en) 2021-12-16
JP2025172140A (ja) 2025-11-20
IL282431A (en) 2021-06-30
EP3870212A4 (en) 2022-11-16
AU2019365654A1 (en) 2021-05-13
JP7798368B2 (ja) 2026-01-14
CN113038965A (zh) 2021-06-25
IL324815A (en) 2026-01-01
IL282431B2 (en) 2026-04-01
AU2019365654A8 (en) 2021-05-20
WO2020086400A1 (en) 2020-04-30
CN120022352A (zh) 2025-05-23
US12110316B2 (en) 2024-10-08
KR20210081372A (ko) 2021-07-01
JP2024009210A (ja) 2024-01-19
CN113038965B (zh) 2025-02-07
JP7426121B2 (ja) 2024-02-01
AU2025200880A1 (en) 2025-03-06
AU2019365654B2 (en) 2024-11-14
IL282431B1 (en) 2025-12-01
CA3116325A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2021004496A (es) Activadores segmentables de cxcr3 y metodos de uso.
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
ECSP19034870A (es) Péptidos escindibles y proteínas insecticidas y nematicidas que los comprenden
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CL2016001405A1 (es) A peptide mixture
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
AR087070A1 (es) Proteinas de fusion liberadoras de relaxina y usos de las mismas
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
CO6210757A2 (es) Proeina de fusion que comprende prame o un fragmento inmunogenico del mismo
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
CO2022008004A2 (es) Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos
CO6331291A2 (es) Peptidos de señalizacion de la crkl
CL2017003201A1 (es) Variantes de il-37
EA202190096A1 (ru) Композиция, содержащая аналог соматостатина, для радиофармацевтического применения
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
MX2023001601A (es) Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
ECSP22090761A (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
CU20200064A7 (es) Expresión de la proteína de superficie neumocócica a (pspa)
ECSP24035412A (es) Dendrones peptídicos y métodos de uso de los mismos